DAPK1 and non-small cell lung carcinoma: Taken together, our results demonstrated that suppression of DANGER expression and/or DAPK-DANGER interaction through treatment of specific agents in combination with radiotherapy in FDG-avid tumors could improve the therapeutic efficacy for treating NSCLC by overcoming radioresistance.